Cancer Drug Reimbursement Facing Possible Reform

Article

As Congress moves toward possible approval of a new prescription drug program for Medicare recipients later this summer, how payments for cancer drugs and therapeutic services are determined may well hang in the balance.

Related Videos
Dr. Suneel Chilukuri
Health Care Impacts on Gender and Sexual Minority Patients
Caring for Gender and Sexual Minority Patients
Related Content

5 Ways to Negotiate the Best Physician Employment Contract

August 28th 2023

The Cutaneous Connection: Episode 18-Cybersecurity Within the Dermatology Practice

February 18th 2021

Disclosing Physician Health: What Is Required?

August 17th 2023

4 Key Tools to Protect Personal and Practice Assets

July 31st 2023

Expert Witness and Perjury

July 31st 2023

FDA Black Box Warning and Liability

June 30th 2023

5 Ways to Negotiate the Best Physician Employment Contract

August 28th 2023

The Cutaneous Connection: Episode 18-Cybersecurity Within the Dermatology Practice

February 18th 2021

Disclosing Physician Health: What Is Required?

August 17th 2023

4 Key Tools to Protect Personal and Practice Assets

July 31st 2023

Expert Witness and Perjury

July 31st 2023

FDA Black Box Warning and Liability

June 30th 2023

5 Ways to Negotiate the Best Physician Employment Contract

August 28th 2023

The Cutaneous Connection: Episode 18-Cybersecurity Within the Dermatology Practice

February 18th 2021

Disclosing Physician Health: What Is Required?

August 17th 2023

4 Key Tools to Protect Personal and Practice Assets

July 31st 2023

Expert Witness and Perjury

July 31st 2023

FDA Black Box Warning and Liability

June 30th 2023
© 2023 MJH Life Sciences

All rights reserved.